Inventor
MICHAEL J. THERIEN
Inventor
US
Overview
Patents· 5 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Nprimary
A61NElectrotherapy16%
A61KPreparations for medical, dental or toiletry purposes12%
A61LMethods or apparatus for sterilising materials or objects in general12%
A61BDiagnosis8%
A61MDevices for introducing media into, or onto, the body8%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations8%
C02FTreatment of water, waste water, sewage, or sludge4%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium4%
H01GCapacitors4%
H01JElectric discharge tubes or discharge lamps4%
PatentTitleYear
12,074,000Iron chromophores for energy conversion202411,589,432Up and down conversion systems for production of emitted light from various energy sources including radio frequency, microwave energy and magnetic induction sources for upconversion202311,571,587Method for treating a disease, disorder, or condition using inhalation to administer an activatable pharmaceutical agent, an energy modulation agent, or both202311,383,098Non-invasive energy upconversion methods and systems for in-situ photobiomodulation202211,324,965Non-invasive energy upconversion methods and systems2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2024Patents assigned to UNIV DUKE (5)· patent assignee history
2022–2023Patents assigned to IMMUNOLIGHT LLC (4)· patent assignee history
2022Patents assigned to IMMUNOLOIGHT LLC (1)· patent assignee history
2022–2024Based in US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| UNIV DUKE | 5 | 2022–2024 |
| IMMUNOLIGHT LLC | 4 | 2022–2023 |
| IMMUNOLOIGHT LLC | 1 | 2022 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 5 | 2022–2024 |